-
公开(公告)号：US20230415378A1
公开(公告)日：2023-12-28
申请号：US18049648
申请日：2022-10-26
Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
Inventor： Daniel Hanoch WAGNER , Mark SHNEIDER
IPC: B29B7/00 , B29B7/10 , D04H1/728 , D04H1/4326 , D01D5/00
CPC classification number: B29B7/005 , B29B7/10 , D01D5/003 , D04H1/4326 , D04H1/728
Abstract: The presently disclosed subject matter relates to the field of electrospun epoxy fibers, a solution for producing the fibers and a system for electrospinning the fibers. This invention further relates to processes of producing the solution and the fibers. By dissolving epoxy in a dielectric solvent, suitable electrospinning conditions are achieved by controlling the degree of epoxy crosslinking in the solution. The fibers are captured on a net screen, with the positive electrode placed behind it. The resulting electrospun fibers exhibit superior mechanical properties in comparison with other epoxy fibers. This improvement in mechanical properties is, in part, due to anisotropic molecular rearrangement resulting from the strong stretching forces induced by electrospinning.
-
32.发明授权公开(公告)号：US11852634B2
公开(公告)日：2023-12-26
申请号：US17081013
申请日：2020-10-27
Inventor： Eran Ovadia , Irun R. Cohen , Johannes Herkel , Raanan Margalit , Meirav Pevsner-Fischer
IPC: G01N33/68 , A61K38/08 , A61K38/18 , A61K31/343 , A61K38/30 , A61K45/06 , C07K7/06 , G01N33/543
CPC classification number: G01N33/6854 , A61K31/343 , A61K38/08 , A61K38/185 , A61K38/1808 , A61K38/1825 , A61K38/1833 , A61K38/1841 , A61K38/1866 , A61K38/1891 , A61K38/30 , A61K45/06 , C07K7/06 , G01N33/54306 , G01N33/6896 , G01N2800/28 , G01N2800/52
Abstract: The present invention relates to uses of a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, analogues and derivatives thereof, for the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS). The present invention further provides a method for assessing responsiveness to treatment with the peptide of the invention. In addition, the present invention relates to prognosis of ALS progression, using Akt and phosphorylated Akt as biomarkers.
-
公开(公告)号：US20230256028A1
公开(公告)日：2023-08-17
申请号：US18137449
申请日：2023-04-21
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Yair REISNER , Carmit HILLEL-KARNIEL , Chava ROSEN , Esther BACHAR-LUSTIG , Elias SHEZEN
CPC classification number: A61K35/42 , A61P11/00 , A61K9/0019 , A61K35/28
Abstract: A method of treating a pulmonary disorder or injury in a subject in need thereof is disclosed. The method comprising administering to the subject non-syngeneic pulmonary tissue cells in suspension comprising an effective amount of hematopoietic precursor cells (HPCs) or supplemented with HPCs, wherein the effective amount is a sufficient amount to achieve tolerance to the pulmonary tissue cells in the absence of chronic immunosuppressive regimen. A method of inducing donor specific tolerance in a subject in need of a pulmonary cell or tissue transplantation is also disclosed.
-
公开(公告)号：US11684578B2
公开(公告)日：2023-06-27
申请号：US16485855
申请日：2018-02-16
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Jacob Klein , Ronit Goldberg , Weifeng Lin
CPC classification number: A61K9/1273 , A61K9/0019 , A61P19/02
Abstract: A liposome for use in delivering a therapeutically active agent to a subject in need thereof is disclosed herein. The liposome comprises:
a) at least one bilayer-forming lipid;
b) a polymeric compound having the general formula I:
wherein m, n, L, X, Y, and Z are as defined herein; and
c) a therapeutically active agent, incorporated in the liposome and/or on a surface of the liposome.-
35.发明公开公开(公告)号：US20230183350A1
公开(公告)日：2023-06-15
申请号：US17806187
申请日：2022-06-09
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Michal Eisenbach-Schwartz , Kuti Baruch , Neta Rosenzweig
IPC: C07K16/28 , A61K39/395 , A61K31/4155 , A61K31/7068 , A61K31/404 , A61K33/36 , A61K45/06 , A61P25/16 , A61P37/06 , A61P25/28 , A61P27/02
CPC classification number: C07K16/2827 , C07K16/2818 , C07K16/2803 , A61K39/3955 , A61K31/4155 , A61K39/395 , A61K39/39541 , A61K31/7068 , A61K31/404 , A61K33/36 , A61K45/06 , A61P25/16 , A61P37/06 , A61P25/28 , A61P27/02 , A61K2039/545
Abstract: The present specification discloses a pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS. The pharmaceutical composition is administered by a dosage regimen comprising at least one course of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.
-
Patent Agency Ranking
公开(公告)号：US20230091945A1
公开(公告)日：2023-03-23
申请号：US17798415
申请日：2021-02-10
Applicant: THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO , THE REGENTS OF THE UNIVERSITY OF CALIFORNIA , YEDA RESEARCH AND DEVELOPMENT CO. LTD.
Inventor： Molly S. SHOICHET , Marian H. HETTIARATCHI , Teresa R. O'MEARA , Matthew J. O'MEARA
Abstract: The present application provides a Chondroitinase ABC (ChABC) mutants. ChABC stimulates axonal regeneration by degrading the inhibitory chondroitin sulfate (CS) and dermatan sulfate (DS) proteoglycans in the glial scar that forms after traumatic injuries to the central nervous system (CNS). However, the therapeutic utility of this potent, fragile protein is severely limited by rapid aggregation at physiological temperature. To overcome this limitation, the ChABC mutants were engineered to at least 15 point mutations in domain 2 of the wild-type ChABC and/or at least 5 point mutations in domain 3 of the wild-type enzyme. These mutants exhibit improved stability over wild-type ChABC. The present application further provides method and compositions comprising the mutant ChABC for treating conditions associated with excess proteoglycan formation or conditions for which treatment is benefitted by degradation of proteoglycans, including CNS injuries, scarring and cancer.
-
公开(公告)号：US20230058044A1
公开(公告)日：2023-02-23
申请号：US17779704
申请日：2020-11-25
Applicant: RAMOT AT TEL-AVIV UNIVERSITY LTD. , ICHILOV TECH LTD. , YEDA RESEARCH AND DEVELOPMENT CO. LTD.
Inventor： Vered PADLER-KARAVANI , Yafit ATIYA-NASAGI , Ron AMON , Anat GLOBERSON LEVIN , Tova WAKS , Moran RAWET-SLOBODKIN , Lihi NINIO MANY , Zelig ESHHAR
IPC: A61K35/17 , C07K14/725 , C07K14/705 , C07K14/735 , C12N5/0783
Abstract: The present invention discloses chimeric antigen receptors that specifically recognize and bind to SLe A carbohydrate antigen with high specificity and selectivity. The invention further provides lymphocytic cells, such as T cells, comprising said CARs, compositions comprising said cells or CARs as well as uses thereof.
-
公开(公告)号：US11576251B2
公开(公告)日：2023-02-07
申请号：US17255519
申请日：2019-06-24
Applicant: Ecole Polytechnique , Ecole Nationale Supérieure de Techniques Avancées , Centre National de La Recherche Scientifique , Yeda Research and Development Co. Ltd.
Inventor： Cédric Thaury , Slava Smartsev
Abstract: A reflective optical system (100) comprising at least one reflective aspheric surface (1) of focal length f0 and optical axis (Z), the surface being configured so that an incident laser beam (2) propagating along an axis (Z′) is focused along the optical axis (Z) with a FWHM ((Full Width at Half Maximum) of the intensity of the reflected beam along the optical axis (Z) being larger, preferably by a factor of at least 10, than the FWHM of the intensity of a focused beam reflected by a parabola having same focal length f0 and same optical axis (Z), receiving same beam.
-
公开(公告)号：US11555178B2
公开(公告)日：2023-01-17
申请号：US16478477
申请日：2018-01-18
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Yair Reisner , Esther Bachar-Lustig , Shlomit Reich-Zeliger
IPC: C12N5/0783 , A61P35/02 , A61P35/04 , A61P35/00 , A61K35/17 , C07K14/725 , C07K16/28 , C07K16/30 , C07K16/32 , C12N5/00 , A61K38/00
Abstract: An isolated cytotoxic T-lymphocyte (CTL), said CTL being a tolerance inducing cell and substantially depleted of alloreactivity, and wherein said CTL does not comprise a central memory T-lymphocyte (Tcm) phenotype, the CTL being transduced to express a cell surface receptor comprising a T cell receptor signaling module, is disclosed. Methods of generating same and using same are also disclosed.
-
公开(公告)号：US11541008B2
公开(公告)日：2023-01-03
申请号：US16809816
申请日：2020-03-05
Applicant: YEDA RESEARCH AND DEVELOPMENT CO., LTD. , YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD.
Inventor： Jacob Klein , Ronit Goldberg , Yechezkel Barenholtz , Avi Schroeder
Abstract: The invention provides a method for lubricating one or more surfaces, comprising applying gel-phase liposomes onto said one or more surfaces, wherein the temperature of said surface(s) at the time of lubrication is below the phase transition temperature Tm of said liposomes. The method can be used for lubricating non-biological surfaces, and also for lubricating the surfaces of a biological tissue in a mammalian subject, e.g., for treating joint dysfunction.
-
-
-
-
-
-
-
-
-
Search Results
997
records
(took 0.059 seconds)
